EUVIMEDEUVIMED entdecken
Crossref

Clinical Course After Radical Local Therapy for Oligo‐Recurrence of Nonsmall Cell Lung Cancer

Dai Sonoda iD, Raito Maruyama, Yasuto Kondo, Shunsuke Mitsuhashi, Satoru Tamagawa iD, Masahito Naito iD, Masashi Mikubo iD, Kazu Shiomi iD, Yukitoshi Satoh

Journal of Surgical Oncology · 2025

DOI: 10.1002/jso.28032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Dai Sonoda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kitasato University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Radical local therapy is effective for oligo‐recurrence of non‐small cell lung cancer (NSCLC). We retrospectively assessed patients with oligo‐recurrent NSCLC and detailed the clinical course after radical local therapy.

Methods

We analyzed 1028 patients who underwent complete resection for NSCLC. We defined oligo‐recurrence as up to two metachronous recurrences, radical local therapy as local therapy performed with curative intent, and progressive disease as the appearance of new lesions/re‐enlargement of the initial recurrence sites.

Results

Of the 132 patients who developed oligo‐recurrence, 88 received radical local therapy. Fifty‐eight patients had progressive disease. Fifteen patients remained cancer free for > 5 years. Epidermal growth factor receptor ( EGFR ) positivity was associated with disease progression (odds ratio, 3.90; p = 0.025). Active treatment for disease progression (hazard ratio, 2.54; p = 0.012) and the absence of re‐enlarged lesions at sites of radical local therapy for recurrence (hazard ratio, 2.32; p = 0.031) were associated with prolonged post‐recurrence overall survival.

Conclusions

Patients with EGFR mutations who develop oligo‐recurrence should be monitored for disease progression. Re‐enlargement of lesions after radical local therapy was associated with a poor prognosis. A good prognosis can be expected with active treatment, even in the event of disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMaleRetrospective StudiesAgedMiddle AgedErbB ReceptorsDisease ProgressionSurvival RateAged, 80 and overAdultFollow-Up StudiesMutationPrognosis

Stichwörter der Autor:innen

carcinomadisease progressionnonsmall‐cell lungrecurrencerisk factorssurvival

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Thoracic Surgery, Kitasato University Medical Center, Saitama, Japan.

ORCID-Profile: Dai Sonoda, Satoru Tamagawa, Masahito Naito, Masashi Mikubo, Kazu Shiomi

Zitieren

APA

Sonoda, D., Maruyama, R., Kondo, Y., Mitsuhashi, S., Tamagawa, S., Naito, M., Mikubo, M., Shiomi, K., & Satoh, Y. (2025). Clinical Course After Radical Local Therapy for Oligo‐Recurrence of Nonsmall Cell Lung Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.28032

Vancouver

Sonoda D, Maruyama R, Kondo Y, Mitsuhashi S, Tamagawa S, Naito M, et al. Clinical Course After Radical Local Therapy for Oligo‐Recurrence of Nonsmall Cell Lung Cancer. Journal of Surgical Oncology. 2025. doi:10.1002/jso.28032

BibTeX
@article{Sonoda2025,
  author = {Sonoda, Dai and Maruyama, Raito and Kondo, Yasuto and Mitsuhashi, Shunsuke and Tamagawa, Satoru and Naito, Masahito and Mikubo, Masashi and Shiomi, Kazu and Satoh, Yukitoshi},
  title = {Clinical Course After Radical Local Therapy for Oligo‐Recurrence of Nonsmall Cell Lung Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1002/jso.28032}
}
Kostenlos starten →